FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769000982> ?p ?o ?g. }

• W2769000982 endingPage "328" @default.
• W2769000982 startingPage "319" @default.
• W2769000982 abstract "Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients. Methods The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) used computer-generated codes to randomly allocate 10 061 men and women with a history of myocardial infarction to placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months. In a prespecified secondary analysis designed to address the relationship of hsCRP reduction to event reduction in CANTOS, we evaluated the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality according to on-treatment concentrations of hsCRP. We used multivariable modelling to adjust for baseline factors associated with achieved hsCRP and multiple sensitivity analyses to address the magnitude of residual confounding. The median follow-up was 3·7 years. The trial is registered with ClinicalTrials.gov, number NCT01327846. Findings Baseline clinical characteristics did not define patient groups with greater or lesser cardiovascular benefits when treated with canakinumab. However, trial participants allocated to canakinumab who achieved hsCRP concentrations less than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted hazard ratio [HRadj]=0·75, 95% CI 0·66–0·85, p<0·0001), whereas no significant benefit was observed among those with on-treatment hsCRP concentrations of 2 mg/L or above (HRadj=0·90, 0·79–1·02, p=0·11). For those treated with canakinumab who achieved on-treatment hsCRP concentrations less than 2 mg/L, cardiovascular mortality (HRadj=0·69, 95% CI 0·56–0·85, p=0·0004) and all-cause mortality (HRadj=0·69, 0·58–0·81, p<0·0001) were both reduced by 31%, whereas no significant reduction in these endpoints was observed among those treated with canakinumab who achieved hsCRP concentrations of 2 mg/L or above. Similar differential effects were found in analyses of the trial prespecified secondary cardiovascular endpoint (which additionally included hospitalisation for unstable angina requiring unplanned revascularisation) and in sensitivity analyses alternatively based on median reductions in hsCRP, on 50% or greater reductions in hsCRP, on the median percent reduction in hsCRP, in dose-specific analyses, and in analyses using a causal inference approach to estimate the effect of treatment among individuals who would achieve a targeted hsCRP concentration. Interpretation The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment. These data further suggest that lower is better for inflammation reduction with canakinumab. Funding Novartis Pharmaceuticals." @default.
• W2769000982 created "2017-12-04" @default.
• W2769000982 creator A5006169505 @default.
• W2769000982 creator A5008060049 @default.
• W2769000982 creator A5008174614 @default.
• W2769000982 creator A5010466306 @default.
• W2769000982 creator A5011776667 @default.
• W2769000982 creator A5012657143 @default.
• W2769000982 creator A5015845395 @default.
• W2769000982 creator A5017674179 @default.
• W2769000982 creator A5018212759 @default.
• W2769000982 creator A5020090012 @default.
• W2769000982 creator A5020460594 @default.
• W2769000982 creator A5020770082 @default.
• W2769000982 creator A5021267309 @default.
• W2769000982 creator A5021976060 @default.
• W2769000982 creator A5022102417 @default.
• W2769000982 creator A5025555714 @default.
• W2769000982 creator A5025632184 @default.
• W2769000982 creator A5028136226 @default.
• W2769000982 creator A5028480812 @default.
• W2769000982 creator A5030391700 @default.
• W2769000982 creator A5036571123 @default.
• W2769000982 creator A5037322697 @default.
• W2769000982 creator A5037858868 @default.
• W2769000982 creator A5038384001 @default.
• W2769000982 creator A5041415060 @default.
• W2769000982 creator A5041635060 @default.
• W2769000982 creator A5043201732 @default.
• W2769000982 creator A5049411694 @default.
• W2769000982 creator A5052604218 @default.
• W2769000982 creator A5053118909 @default.
• W2769000982 creator A5053554163 @default.
• W2769000982 creator A5054214605 @default.
• W2769000982 creator A5057446742 @default.
• W2769000982 creator A5058880971 @default.
• W2769000982 creator A5059884953 @default.
• W2769000982 creator A5060669218 @default.
• W2769000982 creator A5062359201 @default.
• W2769000982 creator A5062764105 @default.
• W2769000982 creator A5063852420 @default.
• W2769000982 creator A5064284791 @default.
• W2769000982 creator A5067385718 @default.
• W2769000982 creator A5074122228 @default.
• W2769000982 creator A5077848934 @default.
• W2769000982 creator A5079090451 @default.
• W2769000982 creator A5079184242 @default.
• W2769000982 creator A5080427269 @default.
• W2769000982 creator A5081510830 @default.
• W2769000982 creator A5081677785 @default.
• W2769000982 creator A5082084514 @default.
• W2769000982 creator A5083111944 @default.
• W2769000982 creator A5083803770 @default.
• W2769000982 creator A5084037972 @default.
• W2769000982 creator A5085731615 @default.
• W2769000982 creator A5088139676 @default.
• W2769000982 creator A5088396929 @default.
• W2769000982 creator A5091595592 @default.
• W2769000982 date "2018-01-01" @default.
• W2769000982 modified "2023-10-16" @default.
• W2769000982 title "Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial" @default.
• W2769000982 cites W1520609538 @default.
• W2769000982 cites W1552829599 @default.
• W2769000982 cites W2027415701 @default.
• W2769000982 cites W2074115529 @default.
• W2769000982 cites W2094941678 @default.
• W2769000982 cites W2096079570 @default.
• W2769000982 cites W2102899779 @default.
• W2769000982 cites W2113275926 @default.
• W2769000982 cites W2118154631 @default.
• W2769000982 cites W2119475547 @default.
• W2769000982 cites W2127469535 @default.
• W2769000982 cites W2137983259 @default.
• W2769000982 cites W2159449551 @default.
• W2769000982 cites W2164353181 @default.
• W2769000982 cites W2285780972 @default.
• W2769000982 cites W2316243284 @default.
• W2769000982 cites W2596179513 @default.
• W2769000982 cites W2596236174 @default.
• W2769000982 cites W2748400555 @default.
• W2769000982 cites W2748800769 @default.
• W2769000982 cites W2750254726 @default.
• W2769000982 cites W3001764054 @default.
• W2769000982 doi "https://doi.org/10.1016/s0140-6736(17)32814-3" @default.
• W2769000982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29146124" @default.
• W2769000982 hasPublicationYear "2018" @default.
• W2769000982 type Work @default.
• W2769000982 sameAs 2769000982 @default.
• W2769000982 citedByCount "567" @default.
• W2769000982 countsByYear W27690009822017 @default.
• W2769000982 countsByYear W27690009822018 @default.
• W2769000982 countsByYear W27690009822019 @default.
• W2769000982 countsByYear W27690009822020 @default.
• W2769000982 countsByYear W27690009822021 @default.
• W2769000982 countsByYear W27690009822022 @default.
• W2769000982 countsByYear W27690009822023 @default.
• W2769000982 crossrefType "journal-article" @default.
• W2769000982 hasAuthorship W2769000982A5006169505 @default.

• next